LIBRETTO-431: Selpercatinib in treatment (Tx)-naive patients with RET fusion-positive (RET plus ) non-small cell lung cancer (NSCLC)

被引：2

作者：

Loong, H. H. F. ^{[1
]}

Goto, K. ^{[2
]}

Elamin, Y. Y. ^{[3
]}

Solomon, B. ^{[4
]}

Santini, F. C. ^{[5
]}

Soldatenkova, V. ^{[6
]}

Sashegyi, A. ^{[6
]}

Lin, A. Bence ^{[6
]}

Lin, B. K. ^{[6
]}

Wolf, J. ^{[7
]}

Oxnard, G. R. ^{[8
]}

Zhou, C. ^{[9
]}

Drilon, A. ^{[10
]}

Park, K. ^{[11
]}

机构：

[1] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Peoples R China

[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[3] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[4] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[5] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil

[6] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA

[7] Univ Hosp Cologne, Oncol, Cologne, Germany

[8] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[9] Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China

[10] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Early Drug Dev Serv, New York, NY USA

[11] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Div Heamatol Oncol, Seoul, South Korea

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.1727

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1413TiP

引用

页码：S893 / S893

页数：1